Insider Buying: InspireMD, Inc. (NYSE:NSPR) Director Buys 20,661 Shares of Stock

Key Points

• InspireMD, Inc. Director Paul Stuka acquired 20,661 shares at an average price of $2.42, increasing his total ownership to 444,195 shares.
• The company's stock is currently trading at around $2.69, with a market capitalization of $82.41 million and a PE ratio of -3.59.
• Recent institutional investments include a 38.4% increase in holdings by Nantahala Capital Management LLC during the first quarter, reflecting growing interest in InspireMD among hedge funds.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Paul Stuka purchased 20,661 shares of the company's stock in a transaction dated Wednesday, July 30th. The stock was bought at an average price of $2.42 per share, with a total value of $49,999.62. Following the completion of the transaction, the director directly owned 444,195 shares of the company's stock, valued at approximately $1,074,951.90. This represents a 4.88% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

InspireMD Trading Down 2.6%

NYSE:NSPR traded down $0.07 during trading hours on Tuesday, hitting $2.60. The company's stock had a trading volume of 48,585 shares, compared to its average volume of 103,497. The stock has a market capitalization of $79.65 million, a P/E ratio of -3.47 and a beta of 0.60. The stock has a fifty day moving average of $2.43 and a 200-day moving average of $2.61. InspireMD, Inc. has a 52-week low of $1.99 and a 52-week high of $3.80.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wall Street Zen assumed coverage on InspireMD in a research report on Monday, May 5th. They issued a "sell" rating for the company. Piper Sandler lowered their price objective on InspireMD from $4.50 to $4.00 and set an "overweight" rating for the company in a research report on Monday, May 12th.

Hedge Funds Weigh In On InspireMD

Hedge funds have recently made changes to their positions in the company. Uniting Wealth Partners LLC purchased a new position in shares of InspireMD during the first quarter worth about $27,000. Brown Advisory Inc. acquired a new stake in InspireMD in the first quarter valued at about $27,000. Renaissance Technologies LLC acquired a new stake in InspireMD in the fourth quarter valued at about $27,000. XTX Topco Ltd acquired a new stake in InspireMD in the first quarter valued at about $38,000. Finally, Vestia Personal Wealth Advisors acquired a new stake in InspireMD in the second quarter valued at about $41,000. Hedge funds and other institutional investors own 44.78% of the company's stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.